The role of neuroinflammation on the pathogenesis of Parkinson’s disease

키워드

참고문헌 (79)

1. Dauer, W., "Parkinson's disease: mechanisms and models", Neuron, 39, pp.889~909 (2003)
2. Savitt, J. M., "Diagnosis and treatment of Parkinson disease: molecules to medicine", J. Clin. Invest., 116, pp.1744~1754 (2006)
3. Greenfield, J. G., "The brainstem lesions in Parkinsonism", J. Neurol. Neurosurg. Psychiatry, 16, pp.213~226 (1953)
4. Braak, H., "Staging of brain pathology related to sporadic Parkinson's disease", Neurobiol. Aging, 24, pp.197~211 (2003)
5. Meredith, G. E., "Animal models of Parkinson's disease progression. Acta", Neuropathol., 115, pp.385~398 (2008)
6. Chesselet, M. F., "In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?", Exp. Neurol., 209, pp.22~27 (2008)
7. Fornai, F., "Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alphasynuclein", Proc. Natl. Acad. Sci. U.S.A., 통권 : 102, pp.3413~3418 (2005)
8. Stack, E. C., "Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease", Biochim. Biophys. Acta., 1782, pp.151~162 (2008)
9. Miller, R. L., "Oxidative and inflammatory pathways in Parkinson's disease", Neurochem. Res., 34, pp.55~65 (2009)
10. Block, M. L., "Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism", Prog. Neurobiol., 76, pp.77~98 (2005)
11. Choi, D. K., "Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice", J. Neurosci., 25, pp.6594~6600 (2005)
12. Hirsch, E. C., "Neuroinflammation in Parkinson's disease: a target for neuroprotection?", Lancet. Neurol., 8, pp.382~397 (2009)
13. Lawson, L. J., "Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain", Neuroscience, 39, pp.151~170 (1990)
14. Morris, L., "Macrophages in haemopoietic and other tissues of the developing mouse detected by the monoclonal antibody F4", 80, 1991, pp.112, 517~526
15. Nimmerjahn, A., "Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo", Science, 308, pp.1314~1318 (2005)
16. Giulian, D., "Microglial mitogens are produced in the developing and injured mammalian brain", J. Cell. Biol., 112, pp.323~333 (1991)
17. Kreutzberg, G. W., "Microglia: a sensor for pathological events in the CNS", Trends. Neurosci., 19, pp.312~318 (1996)
18. Stence, N., "Dynamics of microglial activation: a confocal time-lapse analysis in hippocampal slices", Glia, 33, pp.256~266 (2001)
19. Woodroofe, M. N., "Immunocytochemical characterisation of the immune reaction in the central nervous system in multiple sclerosis. Possible role for microglia in lesion growth", J. Neurol. Sci., 74, pp.135~152 (1986)
20. Graeber, M. B., "Axotomy of the rat facial nerve leads to increased CR3 complement receptor expression by activated microglial cells", J. Neurosci. Res., 21, pp.18~24 (1988)
21. Kim, S. U., "Microglia in health and disease", J. Neurosci. Res., 81, pp.302~313 (2005)
22. Orr, C. F., "An inflammatory review of Parkinson's disease", Prog. Neurobiol., 68, pp.325~340 (2002)
23. Hirsch, E. C., "Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?", Ann. Neurol., 44, pp.S115~S120 (1998)
24. McGeer, P. L., "Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains", Neurology, 38, pp.1285~1291 (1988)
25. Whitton, P. S., "Inflammation as a causative factor in the aetiology of Parkinson's disease", Br. J. Pharmacol., 150, pp.963~976 (2007)
26. Choi, S. H., "Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo", J. Neurosci., 23, pp.5877~5886 (2003)
27. Kim, S. R., "Prothrombin kringle-2 induces death of mesencephalic dopaminergic neurons in vivo and in vitro via microglial activation", J. Neurosci. Res. (2009)
28. Gao, H. M., "Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease", FASEB J., 17, pp.1954~1956 (2003)
29. Liberatore, G. T., "Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease", Nat. Med., 5, pp.1403~1409 (1999)
30. Wu, D. C., "Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease", J. Neurosci., 22, pp.1763~1771 (2002)
31. Wu, D. C., "NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine model of Parkinson's disease", Proc. Natl. Acad. Sci. U.S.A., 통권 : 100, pp.6145~6150 (2003)
32. Tieu, K., "Nitric oxide and reactive oxygen species in Parkinson's disease", IUBMB Life, 55, pp.329~335 (2003)
33. Arimoto, T., "Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration", Neurobiol. Dis., 12, pp.35~45 (2003)
34. Qin, L., "Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress", FASEB J., 19, pp.550~557 (2005)
35. Rodriguez-Pallares, J., "Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamineinduced degeneration of dopaminergic neurons", J. Neurochem., 103, pp.145~156 (2007)
36. Choi, S. H., "Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo", J. Neurochem., 95, pp.1755~1765 (2005)
37. Block, M. L., "Chronic microglial activation and progressive dopaminergic neurotoxicity", Biochem. Soc. Trans., 35, pp.1127~1132 (2007)
38. Hunot, S., "Nitric oxide synthase and neuronal vulnerability in Parkinson's disease", Neuroscience, 72, pp.355~363 (1996)
39. Knott, C., "Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2", Mol. Cell. Neurosci., 16, pp.724~739 (2000)
40. Le, W. D., "Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells", Arch. Neurol., 56, pp.194~200 (1999)
41. Mogi, M., "Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease", Neurosci. Lett., 211, pp.13~16 (1996)
42. Mogi, M., "Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients", Neurosci. Lett., 165, pp.208~210 (1994)
43. Ferger, B., "Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum", J. Neurochem., 89, pp.822~833 (2004)
44. Godoy, M. C., "Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease", Brain, 131, pp.1880~1894 (2008)
45. Klevenyi, P., "Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity", Neuroreport, 10, pp.635~638 (1999)
46. Sriram, K., "Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease", FASEB J., 16, pp.1474~1476 (2002)
47. Tower, D. B., "The activities of butyrylcholinesterase and carbonic anhydrase, the rate of anaerobic glycolysis, and the question of a constant density of glial cells in cerebral cortices of various mammalian species from mouse to whale", J. Neurochem., 20, pp.269~278 (1973)
48. Gordon, G. R., "Brain metabolism dictates the polarity of astrocyte control over arterioles", Nature, 456, pp.745~749 (2008)
49. Mulligan, S. J., "Calcium transients in astrocyte endfeet cause cerebrovascular constrictions", Nature, 431, pp.195~199 (2004)
50. Danbolt, N. C., "Glutamate uptake", Prog. Neurobiol., 65, pp.1~105 (2001)
51. Anastasia, A., "Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson's disease", J. Neurochem., 109, pp.755~765 (2009)
52. Wilhelmsson, U., "Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury", Proc. Natl. Acad. Sci. U.S.A., 통권 : 103, pp.17513~17518 (2006)
53. Nutt, J. G., "Clinical practice. Diagnosis and initial management of Parkinson's disease", N. Engl. J. Med., 353, pp.1021~1027 (2005)
54. McGeer, P. L., "Glial reactions in Parkinson's disease", Mov. Disord., 23, pp.474~483 (2008)
55. Siegel, G. J., "Neurotrophic factors in Alzheimer's and Parkinson's disease brain", Brain. Res. Brain. Res. Rev., 33, pp.199~227 (2000)
56. Saavedra, A., "Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk", Neurobiol. Dis., 23, pp.533~542 (2006)
57. Sandhu, J. K., "Astrocyte-secreted GDNF and glutathione antioxidant system protect neurons against 6OHDA cytotoxicity", Neurobiol. Dis., 33, pp.405~414 (2009)
58. Chen, P. S., "Valproate protects dopaminergic neurons in midbrain neuron", glia cultures by stimulating the release of neurotrophic factors from astrocytes, 2006, pp.11, 1116~1125
59. Knott, C., "Elevated glial brain-derived neurotrophic factor in Parkinson's diseased nigra", Parkinsonism. Relat. Disord., 8, pp.329~341 (2002)
60. Voutilainen, M. H., "Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease", J. Neurosci., 29, pp.9651~9659 (2009)
61. Morale, M. C., "Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration", Neuroscience, 138, pp.869~878 (2006)
62. Min, K. J., "Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation", J. Neurosci., 26, pp.1880~1887 (2006)
63. Jakel, R. J., "Nrf2-mediated protection against 6-hydroxydopamine", Brain Res., 1144, pp.192~201 (2007)
64. Siebert, A., "Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures", J. Neurosci. Res., 87, pp.1659~1669 (2009)
65. Popescu, B. O., "Blood-brain barrier alterations in ageing and dementia", J. Neurol. Sci., 283, pp.99~106 (2009)
66. Persidsky, Y., "Blood-brain barrier: structural components and function under physiologic and pathologic conditions", J. Neuroimmune. Pharmacol., 1, pp.223~236 (2006)
67. Zlokovic, B. V., "The blood-brain barrier in health and chronic neurodegenerative disorders", Neuron, 57, pp.178~201 (2008)
68. Kortekaas, R., "Blood-brain barrier dysfunction in parkinsonian midbrain in vivo", Ann. Neurol., 57, pp.176~179 (2005)
69. Faucheux, B. A., "Blood vessels change in the mesencephalon of patients with Parkinson's disease", Lancet, 353, pp.981~982 (1999)
70. Yasuda, T., "Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease", Exp. Neurol., 206, pp.308~317 (2007)
71. Rite, I., "Bloodbrain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons", J. Neurochem., 101, pp.1567~1582 (2007)
72. Chen, X., "Caffeine protects against MPTP-induced bloodbrain barrier dysfunction in mouse striatum", J. Neurochem., 107, pp.1147~1157 (2008)
73. Yan, E., "Cerebrovascular responses in the fetal sheep brain to low-dose endotoxin", Pediatr. Res., 55, pp.855~863 (2004)
74. Ji, K. A., "Resident microglia die and infiltrated neutrophils and monocytes become major inflammatory cells in lipopolysaccharide-injected brain", Glia, 55, pp.1577~1588 (2007)
75. Brochard, V., "Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease", J. Clin. Invest., 119, pp.182~192 (2009)
76. Li, G., "Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage", FASEB J., 19, pp.489~496 (2005)
77. Ghosh, A., "Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease", J. Neurosci., 29, pp.13543~13556 (2009)
78. Kurkowska-Jastrzebska, I., "Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice", Int Immunopharmacol, 2, pp.1213~1218 (2002)
79. Kurkowska-Jastrzebska, I., "Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease", Int. Immunopharmacol., 4, pp.1307~1318 (2004)

관련 논문AI추천